Beranda › Sklerosis Multipel › Pennsylvania
Uji klinis Sklerosis Multipel di Pennsylvania
7 studi untuk Sklerosis Multipel mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Thomas Jefferson University, Jefferson Headache Center, Philadelphia
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06782490A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Bethlehem
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06433752Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Pennsylvania, Philadelphia
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07002034Genes and Environment in Multiple Sclerosis
- University of Pittsburgh, Pittsburgh
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT01353547Central Vein Sign in Multiple Sclerosis Extension Study
- University of Pennsylvania, Philadelphia
Menerima peserta
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT07424027Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
- University of Pittsburgh, Pittsburgh
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 7 ke atas · Semua jenis kelamin · Diperbarui 29 Des 2025 · NCT02994121Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.